Exact Sciences Corporation vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
4.7
Bearish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
EXAS
Healthy balance sheet and financial position.
⚠ currently unprofitable (-6% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
HOLD
Target $106.30 (+1.3%)
10 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
EXAS
JNJ
—
Trailing P/E
26.3×
55.2×
Forward P/E
17.9×
-6.4%
Profit Margin
21.8%
69.7%
Gross Margin
68.0%
-8.7%
ROE
26.4%
23.1%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
1.44
Beta
0.33
—
Price / Book
—
$20.0B
Market Cap
$546.9B
$39 – $105
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →